NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NKGen Biotech (Nasdaq: NKGN), a clinical-stage biotechnology company specializing in NK cell therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. Paul Y. Song, MD, Chairman and CEO of NKGen, will deliver a virtual presentation and engage in one-on-one meetings with investors.
Key points:
- The virtual presentation will be available on-demand starting September 9, 2024, at 7:00 AM Eastern Time
- Registered participants can submit questions after the presentation
- A webcast of the pre-recorded presentation will be accessible on NKGen's website
- The webcast replay will be available for 90 days following the presentation
This event provides an opportunity for NKGen to showcase its innovative NK cell therapeutics and engage with potential investors.
NKGen Biotech (Nasdaq: NKGN), una società biotecnologica in fase clinica specializzata in terapie con cellule NK, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright che si terrà dal 9 all'11 settembre 2024. Paul Y. Song, MD, Presidente e CEO di NKGen, terrà una presentazione virtuale e parteciperà a incontri individuali con gli investitori.
Punti chiave:
- La presentazione virtuale sarà disponibile on-demand a partire dal 9 settembre 2024, alle 7:00 AM ora orientale
- I partecipanti registrati possono inviare domande dopo la presentazione
- Un webcast della presentazione preregistrata sarà accessibile sul sito web di NKGen
- La riproduzione del webcast sarà disponibile per 90 giorni dopo la presentazione
Questo evento offre a NKGen l'opportunità di mostrare le sue innovative terapie con cellule NK e interagire con potenziali investitori.
NKGen Biotech (Nasdaq: NKGN), una compañía biotecnológica en etapa clínica especializada en terapias con células NK, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright que se llevará a cabo del 9 al 11 de septiembre de 2024. Paul Y. Song, MD, Presidente y CEO de NKGen, realizará una presentación virtual y participará en reuniones uno a uno con inversionistas.
Puntos clave:
- La presentación virtual estará disponible bajo demanda a partir del 9 de septiembre de 2024 a las 7:00 AM Hora del Este
- Los participantes registrados pueden enviar preguntas después de la presentación
- Un webcast de la presentación pregrabada estará accesible en el sitio web de NKGen
- La repetición del webcast estará disponible por 90 días después de la presentación
Este evento representa una oportunidad para que NKGen muestre sus terapias innovadoras con células NK e interactúe con posibles inversionistas.
NKGen Biotech (Nasdaq: NKGN)는 NK 세포 치료제 전문의 임상 단계 생명공학 회사로서, H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 2024년 9월 9일부터 11일까지 참여한다고 발표했습니다. Paul Y. Song, MD는 NKGen의 회장 겸 CEO로서 가상 발표를 진행하고 투자자들과의 일대일 회의에 참여할 예정입니다.
주요 사항:
- 가상 발표는 2024년 9월 9일 오전 7시 미국 동부 표준시부터 주문형으로 제공됩니다.
- 등록된 참가자는 발표 후 질문을 제출할 수 있습니다.
- 사전 녹화된 발표의 웹캐스트는 NKGen의 웹사이트에서 접근할 수 있습니다.
- 웹캐스트 재생은 발표 후 90일 동안 이용 가능합니다.
이번 행사는 NKGen이 혁신적인 NK 세포 치료제를 선보이고 잠재적인 투자자들과 소통할 수 있는 기회를 제공합니다.
NKGen Biotech (Nasdaq: NKGN), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapeutiques à base de cellules NK, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright qui se tiendra du 9 au 11 septembre 2024. Paul Y. Song, MD, Président et CEO de NKGen, fera une présentation virtuelle et participera à des réunions individuelles avec des investisseurs.
Points clés :
- La présentation virtuelle sera disponible à la demande à partir du 9 septembre 2024 à 7h00, heure de l'Est
- Les participants enregistrés peuvent soumettre des questions après la présentation
- Un webcast de la présentation préenregistrée sera accessible sur le site web de NKGen
- La rediffusion du webcast sera disponible pendant 90 jours après la présentation
Cet événement offre à NKGen l'opportunité de présenter ses thérapeutiques innovantes à base de cellules NK et d'interagir avec des investisseurs potentiels.
NKGen Biotech (Nasdaq: NKGN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf NK-Zelltherapeutika spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright vom 9. bis 11. September 2024 angekündigt. Paul Y. Song, MD, Vorsitzender und CEO von NKGen, wird eine virtuelle Präsentation halten und sich in Einzelgesprächen mit Investoren austauschen.
Wichtige Punkte:
- Die virtuelle Präsentation wird ab dem 9. September 2024 um 7:00 Uhr Eastern Time on-demand verfügbar sein.
- Registrierte Teilnehmer können nach der Präsentation Fragen einreichen.
- Ein Webcast der vorab aufgezeichneten Präsentation wird auf der Website von NKGen zugänglich sein.
- Die Wiederholung des Webcasts wird für 90 Tage nach der Präsentation verfügbar sein.
Diese Veranstaltung bietet NKGen die Gelegenheit, seine innovativen NK-Zelltherapeutika vorzustellen und mit potenziellen Investoren in Kontakt zu treten.
- None.
- None.
SANTA ANA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and CEO of NKGen, will participate in a virtual presentation and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, on September 9-11, 2024.
The virtual presentation will be available on-demand for registered participants through the H.C. Wainwright conference portal starting at 7:00 AM Eastern Time on Monday, September 9, 2024. Registered participants can submit their questions to NKGen after the presentation has become available. Dr. Song will also be available for virtual one-on-one investor meetings during the conference.
For more information about the conference and to register for a one-on-one meeting, please visit the conference website at https://hcwevents.com/annualconference/
A webcast of the pre-recorded presentation can be accessed under the Events and Presentations page in the Investors section of the Company’s website at www.nkgenbiotech.com. An archived replay of the webcast will be available for 90 days following the presentation.
About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
Forward-Looking Statements
Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s plans and expected timing for developing SNK01 and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Internal Contact:
Denise Chua, MBA, CLS, MT (ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@nkgenbiotech.com
External Contacts:
Chris Calabrese
Managing Director
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
FAQ
When is NKGen Biotech (NKGN) presenting at the H.C. Wainwright Global Investment Conference?
Who will represent NKGen Biotech (NKGN) at the H.C. Wainwright conference?
How can investors access NKGen Biotech's (NKGN) presentation at the H.C. Wainwright conference?
How long will the replay of NKGen Biotech's (NKGN) presentation be available?
